Abstract Number: PB0294
Meeting: ISTH 2021 Congress
Theme: COVID and Coagulation » COVID and Coagulation, Clinical
Background: COVID-19 course is characterized of thrombosis complications, respiratory failure, and a multiple organ failure development. One of the central pathogenic mechanism of COVID-19 is endothelial dysfunction which can lead to the hypercoagulability. Studying of the endothelial dysfunction markers in patients with COVID-19 could be useful for improving of disease’s outcomes.
Aims: To estimate potential endothelial damage in COVID-19 patients by measuring biomarkers of endothelial disfunction.
Methods: The study included 221 patients with COVID-19 and 68 healthy controls. We studied ristocetin-cofactor von Willebrand’s factor activity (vWF:RCo, %), antigen von Willebrand’s factor (vWF:Ag,%), and homocysteine (HCY, μmol/l) . STATISTICA 12.0 package was used. Statistical analysis was performed by non-parametric methods (median (Me), 95% confidence interval (95% CI), Mann-Whitney U test), p<0.05 was considered statistically significant.
Results:
| Parameter (Me, 95% CI) | Patients with COVID-19 N=221 |
Controls N=68 |
| vWF:RCo , % | 290,0* (109,7 – 724,5) |
97,0 (63,0 – 144,3) |
| vWF: Ag, % | 225,5* (136,1 – 880,4) |
107,0 (74,6 – 161,7) |
| HCY, μmol/l | 16,1* (7,2 – 36,6) |
10,1 (5,1 – 14,8) |
* – p=0,00001 with controls.
Data are presented in the table. The vWF:RCo activity, vWF:Ag and HCY were significantly higher in patients with COVID-19 than in controls. Higher vWF:Ag was found in patients with fatal outcomes compared recovered patients
(Me-244,0, CI: 216,5-930,0 vs. Me-219 CI: 142,9-829,6, p=0,01).
Conclusions: The increase of vWF:RCo activity, vWF:Ag and HCY may indicate endothelial damage in COVID-19 patients that can lead to hypercoagulability and predispose to thromboembolic complications. High vWF:Ag could be predictive marker of poor outcomes in COVID-19 patients.
To cite this abstract in AMA style:
Matvienko O, Korsakova N, Smirnova O, Lerner A, Shwedova T, Golovina O, Papayan L. Circulating Biologic Markers of Endothelial Dysfunction in COVID-19 Patients [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/circulating-biologic-markers-of-endothelial-dysfunction-in-covid-19-patients/. Accessed November 29, 2023.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/circulating-biologic-markers-of-endothelial-dysfunction-in-covid-19-patients/